Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who have received prior systemic therapies, including an EGFR-directed therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Johnson & Johnson (NYSE:JNJ) Jumps to Year’s High on Lung Cancer Drug Success
- AstraZeneca call volume above normal and directionally bullish
- Hutchmed announces NDA acceptance in China, payment from AstraZeneca
- Levi & Korsinsky LLP Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC(AZN) Shareholders
- AstraZeneca Withdraws Lung Cancer Drug Application in EU
Questions or Comments about the article? Write to editor@tipranks.com